New report highlights the impact of early Grade 1 entry and gender disparities in SA education
Boys entering Grade 1 at the minimum age face higher risks of repetition, while gender disparities widen through to Grade 12 ...
The American Journal of Managed Care10h
FDA Approves Mirdametinib for Neurofibromatosis Type 1 with Plexiform Neurofibromas
Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
Medscape2d
FDA Approves Mirdametinib for Neurofibromatosis Type 1
The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have unresectable symptomatic plexiform neurofibromas.
Medscape3d
Ocular Surface Reconstruction: Recent Innovations, Surgical Candidate Selection and Postoperative Management
Table 1 pools selected studies comparing tissue types, scaffolding materials, overall success rates and complications. Oral-ocular transplantation studies are included here but its discussion will ...